Jakob Dupont
Net Worth

Last updated:

What is Jakob Dupont net worth?

The estimated net worth of Dr. Jakob Dupont is at least $6,445,952 as of 2 Mar 2023. He owns shares worth $3,489,499 as insider, has earned $572,973 from insider trading and has received compensation worth at least $2,383,480 in Atara Biotherapeutics, Inc..

What is the salary of Jakob Dupont?

Dr. Jakob Dupont salary is $595,870 per year as Head of Global R&D in Atara Biotherapeutics, Inc..

How old is Jakob Dupont?

Dr. Jakob Dupont is 60 years old, born in 1965.

What stocks does Jakob Dupont currently own?

As insider, Dr. Jakob Dupont owns shares in one company:

Company Title Shares Price per share Total value
Atara Biotherapeutics, Inc. (ATRA) Head of Global R&D 290,794 $12 $3,489,499

What does Atara Biotherapeutics, Inc. do?

Atara Biotherapeutics, Inc., an off-the-shelf T-cell immunotherapy company, develops treatments for patients with cancer, autoimmune, and viral diseases in the United States. It is developing tabelecleucel, a T-cell immunotherapy that is Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferative disease, as well as hematologic and solid tumors, including nasopharyngeal carcinoma. The company is also developing next-generation CAR T immunotherapies for patients with hematologic malignancies and solid tumors, including ATA2271 and ATA3271 for mesothelin; and ATA2431 and ATA3219 for B-cell malignancies, as well as ATA188 for the treatment of multiple sclerosis. In addition, it develops ATA368 program for patients with human papillomavirus associated cancers. Atara Biotherapeutics, Inc. has a license agreement with Memorial Sloan Kettering Cancer Center; license, and research and development collaboration agreement with QIMR Berghofer Medical Research Institute; and strategic collaboration with H. Lee Moffitt Cancer Center, as well as Bayer AG for mesothelin-targeted CAR T-cell therapies for solid tumors. The company was incorporated in 2012 and is headquartered in South San Francisco, California.

ATRA logo
ATRA
Atara Biotherapeutics, Inc.
$12

Jakob Dupont insider trading

Atara Biotherapeutics, Inc.

Dr. Jakob Dupont has made 13 insider trades between 2021-2023, according to the Form 4 filled with the SEC. Most recently he sold 5,074 units of ATRA stock worth $18,403 on 2 Mar 2023.

The largest trade he's ever made was exercising 5,184 units of ATRA stock on 18 May 2021. As of 2 Mar 2023 he still owns at least 290,794 units of ATRA stock.

Transaction Date Security Shares Price per share Total value Source
Sale
Common Stock 5,074 $3.63 $18,403
Sale
Common Stock 1,124 $4.49 $5,048
Sale
Common Stock 3,218 $4.49 $14,449
Sale
Common Stock 4,124 $5.03 $20,760
Sale
Common Stock 3,873 $5.32 $20,597
Sale
Common Stock 2,221 $9.86 $21,890
Option
Employee Stock Option (Right to Buy) 5,000 $9.58 $47,900
Option
Common Stock 5,000 $9.58 $47,900
Sale
Common Stock 5,000 $16 $80,000
Sale
Common Stock 5,000 $16.01 $80,050
Option
Common Stock 5,000 $9.58 $47,900
Option
Employee Stock Option (Right to Buy) 5,000 $9.58 $47,900
Sale
Common Stock 5,000 $17.94 $89,690
Option
Employee Stock Option (Right to Buy) 5,000 $9.58 $47,900
Option
Common Stock 5,000 $9.58 $47,900
Sale
Common Stock 2,199 $17.12 $37,640
Option
Common Stock 5,000 $9.58 $47,900
Sale
Common Stock 5,000 $16.41 $82,050
Option
Employee Stock Option (Right to Buy) 5,000 $9.58 $47,900
Sale
Common Stock 2,152 $12.53 $26,969
Sale
Common Stock 5,184 $14.55 $75,427

Atara Biotherapeutics key executives

Atara Biotherapeutics, Inc. executives and other stock owners filed with the SEC:

  • Dr. Jakob Dupont (60) Head of Global R&D
  • Dr. Kristin Yarema Ph.D. (54) SVice President & Chief Commercial Officer
  • Dr. Pascal Touchon D.V.M. (62) Pres, Chief Executive Officer & Director
  • Mr. Joseph Newell (55) Executive Vice President & Chief Operating Officer
  • Mr. Utpal Koppikar (54) Chief Financial Officer & SVice President